In the future, we expect obesity care to become much more differentiated, and with BI 3034701, we aim to go beyond short-term weight loss and address both the biological and behavioral drivers of obesity. BI 3034701 is part of a broader portfolio of therapies being developed for people living with obesity or obesity and connected metabolic health conditions, which has multiple approaches under investigation, including survodutide, a dual glucagon/GLP-1 agonist
The body makes L-carnitine from the amino acids lysine and methionine, and its central job is the carnitine shuttle: ferrying long-chain fatty acids across the inner mitochondrial membrane so they can be burned for energy
Pharmacies operating under Section 503A of federal law do not follow all the manufacturing rules imposed on conventional drug companies
tirzepatide has been suggested to be cost-effective compared with s.c
Defy Medical provides access to medication like Zofran as appropriate, which can help with issues like nausea
Pricing is flat across doses, which protects you from escalation creep
